Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase study
L Chouchana, LH Preta, M Tisseyre… - Kidney …, 2021 - kidney-international.org
To the editor Remdesivir is a novel adenosine-like nucleotide analogue, representing the
first drug approved for coronavirus disease 2019 (COVID-19), albeit an uncertain clinical
relevance. In clinical trials and case series, acute kidney injury (AKI), including renal
replacement, has been frequently reported. 1, 2 Although causality is debatable, kidney
injuries, especially proximal tubular epithelial cell necrosis, have also been observed in
animal studies during remdesivir development. To provide additional data, we performed a …
first drug approved for coronavirus disease 2019 (COVID-19), albeit an uncertain clinical
relevance. In clinical trials and case series, acute kidney injury (AKI), including renal
replacement, has been frequently reported. 1, 2 Although causality is debatable, kidney
injuries, especially proximal tubular epithelial cell necrosis, have also been observed in
animal studies during remdesivir development. To provide additional data, we performed a …